Insider Selling: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Insider Sells 7,313 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) insider Aranthan Jones II sold 7,313 shares of the company’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $10.62, for a total transaction of $77,664.06. Following the sale, the insider now directly owns 82,687 shares of the company’s stock, valued at approximately $878,135.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ:VNDA opened at $10.08 on Friday. The firm’s 50 day moving average price is $11.23 and its 200 day moving average price is $11.64. The stock has a market cap of $549.86 million, a price-to-earnings ratio of 4.71 and a beta of 0.54. Vanda Pharmaceuticals Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $17.85.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. The firm had revenue of $58.00 million for the quarter, compared to analysts’ expectations of $57.53 million. Vanda Pharmaceuticals had a net margin of 49.12% and a return on equity of 30.60%. On average, research analysts predict that Vanda Pharmaceuticals Inc. will post 0.31 EPS for the current fiscal year.

VNDA has been the topic of a number of recent analyst reports. BidaskClub cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Citigroup cut shares of Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $14.00 target price on the stock. in a research report on Tuesday, June 9th. ValuEngine cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, May 1st. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $13.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $15.40.

A number of institutional investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. increased its stake in Vanda Pharmaceuticals by 8.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,685 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 889 shares during the last quarter. Swiss National Bank increased its stake in Vanda Pharmaceuticals by 1.4% in the first quarter. Swiss National Bank now owns 93,100 shares of the biopharmaceutical company’s stock valued at $965,000 after purchasing an additional 1,300 shares during the last quarter. James Investment Research Inc. increased its stake in Vanda Pharmaceuticals by 8.3% in the second quarter. James Investment Research Inc. now owns 19,685 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 1,505 shares during the last quarter. Comerica Bank increased its stake in Vanda Pharmaceuticals by 3.2% in the first quarter. Comerica Bank now owns 51,683 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 1,609 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in Vanda Pharmaceuticals by 25.7% in the fourth quarter. Victory Capital Management Inc. now owns 10,190 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 2,084 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: Investing in Blue-Chip Stocks

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.